Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mesenchymal stromal cell-derived extracellular vesicles (IDOR)
- Development stage
- Unknown
- Lead developer
- IDOR
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) are an investigational exosome-based therapy being developed by the D'Or Institute for Research and Education (IDOR). These extracellular vesicles are nano-sized, membrane-bound particles secreted by mesenchymal stromal cells that carry a cargo of bioactive proteins, lipids, and nucleic acids. In the context of acute respiratory distress syndrome (ARDS), MSC-EVs are designed to modulate the pulmonary and systemic inflammatory response, reduce the production of pro-inflammatory cytokines (mitigating the "cytokine storm"), and promote the repair of alveolar epithelial and endothelial barriers. The therapy is administered intravenously and is currently being evaluated in Phase I/II clinical trials for patients with moderate to severe ARDS, including cases associated with SARS-CoV-2 infection.
- Other names
- MSC-EVsExtracellular Vesicles From Mesenchymal CellsEVs from MSCs
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)
Beyond the preview
Go deeper on Mesenchymal stromal cell-derived extracellular vesicles (IDOR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mesenchymal stromal cell-derived extracellular vesicles (IDOR).